Medications for pneumonia
Pro Research Analysisby 
Searched over 200M research papers
Medications for Pneumonia: An Overview
Over-the-Counter (OTC) Medications for Pneumonia
Efficacy of OTC Cough Medications
Cough is a common and distressing symptom for patients with pneumonia, leading many to use OTC cough medications such as mucolytics and cough suppressants. However, the efficacy of these medications as adjuncts to antibiotics in treating pneumonia remains uncertain. Studies have shown that while mucolytics like bromhexine, ambroxol, and neltenexine may reduce the secondary outcome of 'not cured' in both children and adults, there is no significant difference in the primary outcome of 'not cured or not improved' 123. Consequently, there is insufficient evidence to recommend OTC cough medications as a beneficial adjunctive treatment for acute pneumonia. Additionally, it is advised that OTC medications containing codeine and antihistamines should not be used in young children due to potential harm 123.
Emerging Drugs for Nosocomial Pneumonia
New Antibiotics and Combinations
Nosocomial pneumonia, particularly hospital-acquired pneumonia (HAP), poses significant treatment challenges due to multidrug-resistant pathogens. Recent research highlights several promising new drugs and combinations. These include tedizolid, a new oxazolidinone; iclaprim, related to trimethoprim; plazomicin, a new aminoglycoside; and combinations like ceftazidime/avibactam and ceftolozane/tazobactam, which show efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative extended-spectrum beta-lactamase (ESBL) bacteria .
Adjunctive Therapies for Community-Acquired Pneumonia (CAP)
Corticosteroids and Other Therapies
For community-acquired pneumonia (CAP), adjunctive therapies have been explored to enhance treatment outcomes. Corticosteroids have shown promise, particularly in severe cases, by significantly reducing mortality compared to placebo . However, other adjunctive therapies such as activated protein C, non-invasive mechanical ventilation, anticoagulants, immunoglobulin, granulocyte-colony-stimulating factor, statins, probiotics, chest physiotherapy, antiplatelet drugs, beta(2)-agonists, inhaled nitric oxide, and angiotensin-converting enzyme inhibitors have not demonstrated a survival benefit in CAP patients .
Antibiotic Treatments for Pneumonia
Solithromycin vs. Moxifloxacin for CAP
In the treatment of community-acquired bacterial pneumonia (CABP), solithromycin, a novel macrolide, has been compared to moxifloxacin. A global, double-blind, randomized trial found that solithromycin was non-inferior to moxifloxacin in achieving early clinical response, with both drugs showing similar safety profiles . This suggests that solithromycin could be a viable alternative to moxifloxacin, potentially restoring macrolide monotherapy for CABP .
Inhaled Amikacin for Gram-Negative Pneumonia
For mechanically ventilated patients with Gram-negative pneumonia, the combination of inhaled amikacin with standard intravenous antibiotics was investigated. However, the study found no significant difference in survival rates between the amikacin group and the placebo group, indicating that inhaled amikacin does not provide additional benefits as an adjunctive therapy .
Antibiotic Use in Nonsevere Pneumonia in Children
Amoxicillin vs. Placebo
A study conducted in Pakistan evaluated the use of oral amoxicillin versus placebo in children aged 2-59 months with World Health Organization (WHO)-defined nonsevere pneumonia. The results showed no significant difference in clinical outcomes between the amoxicillin and placebo groups, suggesting that many children classified with nonsevere pneumonia may not require antibiotics, which could help reduce unnecessary antibiotic use and resistance .
Conclusion
The treatment of pneumonia involves a variety of medications, including OTC cough medications, emerging antibiotics, and adjunctive therapies. While mucolytics may offer some benefit, their overall efficacy remains inconclusive. New antibiotics and combinations show promise for nosocomial pneumonia, and corticosteroids may be beneficial for severe CAP. However, the use of inhaled amikacin and antibiotics for nonsevere pneumonia in children requires further evaluation. Continued research is essential to optimize pneumonia treatment and reduce antibiotic resistance.
Sources and full results
Most relevant research papers on this topic
Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults.
There is insufficient evidence to recommend over-the-counter cough medications as an adjunctive treatment for acute pneumonia in children and adults.
Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults.
OTC cough medications, such as mucolytics, show no significant difference in primary outcome between children and adults with pneumonia, but may reduce secondary outcomes.
Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults.
OTC medications for cough associated with pneumonia show insufficient evidence to determine their effectiveness as an adjunct to antibiotics in children and adults.
Emerging drugs for nosocomial pneumonia
Emerging drugs like tedizolid, iclaprim, plazomicin, and combinations of ceftazidime/avibactam and ceftolozane/tazobactam show promise for treating hospital-acquired pneumonia, especially against multidrug-resistant bacteria.
Comparison of oral amoxicillin with placebo for the treatment of world health organization-defined nonsevere pneumonia in children aged 2-59 months: a multicenter, double-blind, randomized, placebo-controlled trial in pakistan.
Children aged 2-59 months with WHO-defined nonsevere pneumonia do not experience a different clinical outcome when treated with antibiotics or placebo.
DOI